Mattias Paulsson

Akademiska meriter:

Kort presentation

Licensed pharmacist with a PhD in pharmaceutics. Experience from regulatory, GMP, quality, R&D, compounding, chemotherapy, radiopharmaceuticals. Hospital pharmacy.
Qualified Person Pharmacovigilance for Fludeoxyglucose (18F) Akademiska sjukhuset
Specialties: Pharmaceutics, disperse systems, gels, parenteral nutrition, aseptic compounding.


  • clinical nutrition
  • clinical pharmacy
  • formulation
  • immuno-oncology
  • protein drug
  • radionuclides


Mattias Paulsson obtained his pharmacist degree at Uppsala University, Sweden, in 1997. Thereafter he started his PhD project at the Department of Pharmacy/ Pharmaceutics, Uppsala University presenting his thesis “Controlled Release Gel Formulations for Mucosal Drug Delivery” in 2001. In the thesis, physicochemical principles of pharmacy are used for formulation development for clinical applications.

Dr. Paulsson has held positions as formulation scientist at both Cederroth International and Fresenius Kabi. He has been heading the extemporaneous compounding unit of Uppsala University Hospital, preparing radio­pharmaceuticals, chemotherapy and other aseptically prepared medications as well as managing the clinical trials unit. He has been a qualified person and held positions with GMP-responsibility for compounding units at some Swedish hospitals.

In 2014 he started working with a more clinical approach at the Uppsala University Children’s Hospital with patient safety and optimizing the use of medications from a formulation point of view. He has configured and developed the medication modules of the PDMS system (MetaVision) used at the hospital including the NICU. He holds the position of QPPV (Qualified person pharmacovigilance) for the PET centre at the hospital. He has been managing projects to build new clean rooms, hire staff, purchasing equipment (including chemotherapy robotic automation) and in-sourcing of extemporaneous compounding units for radiotherapy, chemotherapy and miscellaneous aseptic preparations. From 2019 he is deputy chief pharmacist at Uppsala University Hospital and has several research projects running in 3D-printing and protein drug handling, including the EU/EFPIA Innovative Medicines Initiative 2 Joint Un-dertaking (RealHOPE grant).

He is involved in both undergraduate and post graduate training of pharmacist at Uppsala University and in some occasions also in Scandinavian settings in the areas: Parenteral nutrition, IV compatibility, Formulation Science and Compounding. He is supervising one PhD student at the department of Pharmacy, Uppsala university and became Associate professor (Docent) in March 2023.

He has been chairman for the Scandinavian Paediatric Pharmacist Group for 2017-2019 and he was in the steering committee of the ePed Best practice initiative ( for safe handling of paediatric medications based on the EU resolution on medication handling quality. He is a member of UK based Neonatal and Paediatric Pharmacists Group (NPPG) and the Swedish Pharmaceutical Society.


The research questions of Mattias Paulsson focuses on complexities of paediatric medicine administration, addressing the lack of appropriately formulated drugs for children and the challenges associated. The use of new techniques such as additive manufacturing (3D-printing) is evaluated in a multiprofessional, clinically-oriented setting.

Paulsson is also engaged in research closely related to the neonatal intensive care unit and the latest published study explores the effects of different light conditions on oxidative stress markers, providing insights into potential measures to safeguard the nutritional integrity of breast milk for preterm infants.

Paulsson is also part of a European IMI project, RealHOPE, that explores the handling of protein drugs, particularly monoclonal antibodies used in paediatric oncology, emphasizing careful management. Research questions revolve around risk analyses, targeting stress factors affecting drug integrity during the handling/supply chain aiming at mitigating potential threats, including temperature and shock exposure to ensure the quality and safety of protein drugs.

The RealHOPE, a 4 year research project that aims to measure real-life events during drug handling to develop methods for simulating these events. Aiming to propose best practices to hospitals and hospital pharmacies for handling of protein drugs. RealHOPE consist of five work packages that each addresses the five project goals set for the project. The third work package is called HIGH and it will demonstrate and/or have develop new technologies for safer handling of protein drugs at hospital pharmacies. The project team will look at the methods and guidelines in use to improve the handling of drugs in hospital.

Please read more here: RealHOPE |





Senaste publikationer

Alla publikationer





Mattias Paulsson